ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...
Adult patients with severe CRSwNP treated with tezepelumab continued to receive benefit 24 weeks after treatment cessation.
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...
The holiday season brings family gatherings and frequent travel — but for many Scottsdale residents, it also brings sinus ...
The Family Health Care Institute bulletin (one of King Hussein Foundation's institutes), on this Sunday, discusses nasal and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback